Photo by Sangharsh Lohakare on Unsplash
Every major pharmaceutical company on earth has spent decades and billions chasing the same goal: teaching the immune system to recognize and destroy cancer the way it already destroys a virus. It’s one of medicine’s oldest, most expensive, most repeatedly disappointed pursuits.
Ten days ago, one press release suggested someone may have actually gotten close. A personalized vaccine, built on the same platform behind a shot most of the world already has in its arm, hit both primary goals in a late-stage melanoma trial — fewer recurrences, less spread. It’s the first trial of its kind to succeed at this stage. Not a cure, not yet approved — but real. The stock jumped as much as 160% in a single session.
Five days later, on no comparable news, it fell nearly 20% in a day. Same company, same week, same story everyone was still arguing about.
My model doesn’t read headlines. It doesn’t know the stock moved 160%, or that it gave much of it back days later. It ranks all 450+ stocks the same quantitative way, every week — and this week, this one landed at #4.
Signal: BUY.
Capital stays invested — core and pick both.
A free subscription gets you:
Weekly trade signals on SPY, BTC, and GLD + Real-time flip alerts.
The Stock I Buy Every Monday.
Live portfolio performance and holdings.
Every Sunday at 6:00 am ET, free. Subscribe here to get next week’s QuantRank in your inbox.
Disclosure: I personally buy this QuantRank, in the live portfolio, every Monday after publication — never before.
Disclaimer: Educational and informational only. Not personalized investment advice, and not a recommendation to buy or sell any security. I am not a registered investment adviser. Past performance — backtested or live — does not guarantee future results. You can lose money, including a substantial amount. Consult a qualified financial adviser before investing. Full disclosures in The Patala Core-Plus Strategy.